The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Post-transplant FLT3 inhibitor maintenance in AML: evidence and practical considerations
Robert Negrin, MD, Stanford University, Stanford, CA, discusses the growing role of FLT3 inhibitor maintenance therapy following allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML). Prof. Negrin reviews the evidence supporting post-transplant maintenance, particularly with gilteritinib, and discusses key considerations including toxicity management, patient selection, treatment duration, and molecular monitoring using PCR-based assays to detect relapse risk. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
